Pre-Clinical Data with ALN-HBV for the Treatment of Hepatitis B Virus (HBV) Infection

We presented pre-clinical data with ALN-HBV, an RNAi therapeutic targeting the hepatitis B virus (HBV) genome for the treatment of HBV infection, at the TIDES 2014 meeting held May 12 – 15 in Providence, Rhode Island. Specifically, we reported significant, multi-log reductions in HBV surface antigen (HBsAg) and HBV viral titers, and showed evidence for an immune-mediated therapeutic effect in chronically infected chimpanzees.

We believe these data constitute the most robust, proof-of-concept, pre-clinical data to date with an RNAi therapeutic for the treatment of HBV. Our current ALN-HBV RNAi therapeutic represents a potentially powerful mechanism for inhibiting all steps of the HBV life cycle: replication, assembly, secretion of virus, and secretion of sub-viral antigens. Because of its unique mechanism of action to inhibit key steps in the viral life cycle, an RNAi therapeutic targeting the HBV genome could offer the potential for significant efficacy in the treatment of HBV, and a potential route to a “functional cure.” Alnylam plans on advancing ALN-HBV, a subcutaneously administered ESC-GalNAc-siRNA, which we believe could become a best-in-class RNA therapeutic for the treatment of HBV infection.